Clinical College of Armed Police General Hospital of Anhui Medical University, Department of Gastroenterology of The Third Medical Center of Chinese PLA General Hospital, Beijing, 100039, China; CAS Key Laboratory of Molecular Imaging, Beijing Key Laboratory of Molecular Imaging, Institute of Automation, Chinese Academy of Sciences, Beijing, 100190, China.
School of Engineering Medicine, Beihang University, Beijing, 100191, China; Key Laboratory of Big Data-Based Precision Medicine (Beihang University), Ministry of Industry and Information Technology, Beijing, 100191, China.
EBioMedicine. 2023 Mar;89:104476. doi: 10.1016/j.ebiom.2023.104476. Epub 2023 Feb 16.
Surgery is the cornerstone of colorectal cancer (CRC) treatment, yet complete removal of the tumour remains a challenge. The second near-infrared window (NIR-II, 1000-1700 nm) fluorescent molecular imaging is a novel technique, which has broad application prospects in tumour surgical navigation. We aimed to evaluate the ability of CEACAM5-targeted probe for CRC recognition and the value of NIR-II imaging-guided CRC resection.
We constructed the probe 2D5-IRDye800CW by conjugated anti-CEACAM5 nanobody (2D5) with near-infrared fluorescent dye IRDye800CW. The performance and benefits of 2D5-IRDye800CW at NIR-II were confirmed by imaging experiments in mouse vascular and capillary phantom. Then mouse colorectal cancer subcutaneous tumour model (n = 15), orthotopic model (n = 15), and peritoneal metastasis model (n = 10) were constructed to investigate biodistribution of probe and imaging differences between NIR-I and NIR-II in vivo, and then tumour resection was guided by NIR-II fluorescence. Fresh human colorectal cancer specimens were incubated with 2D5-IRDye800CW to verify its specific targeting ability.
2D5-IRDye800CW had an NIR-II fluorescence signal extending to 1600 nm and bound specifically to CEACAM5 with an affinity of 2.29 nM. In vivo imaging, 2D5-IRDye800CW accumulated rapidly in tumour (15 min) and could specifically identify orthotopic colorectal cancer and peritoneal metastases. All tumours were resected under NIR-II fluorescence guidance, even smaller than 2 mm tumours were detected, and NIR-II had a higher tumour-to-background ratio than NIR-I (2.55 ± 0.38, 1.94 ± 0.20, respectively). 2D5-IRDye800CW could precisely identify CEACAM5-positive human colorectal cancer tissue.
2D5-IRDye800CW combined with NIR-II fluorescence has translational potential as an aid to improve R0 surgery of colorectal cancer.
This study was supported by Beijing Natural Science Foundation (JQ19027), the National Key Research and Development Program of China (2017YFA0205200), National Natural Science Foundation of China (NSFC) (61971442, 62027901, 81930053, 92059207, 81227901, 82102236), Beijing Natural Science Foundation (L222054), CAS Youth Interdisciplinary Team (JCTD-2021-08), the Strategic Priority Research Program of the Chinese Academy of Sciences (XDA16021200), the Zhuhai High-level Health Personnel Team Project (Zhuhai HLHPTP201703), the Fundamental Research Funds for the Central Universities (JKF-YG-22-B005) and Capital Clinical Characteristic Application Research (Z181100001718178). The authors would like to acknowledge the instrumental and technical support of the multi-modal biomedical imaging experimental platform, Institute of Automation, Chinese Academy of Sciences.
手术是结直肠癌(CRC)治疗的基石,但完全切除肿瘤仍然是一个挑战。近红外二区(NIR-II,1000-1700nm)荧光分子成像是一种新技术,在肿瘤手术导航中具有广阔的应用前景。我们旨在评估 CEACAM5 靶向探针对 CRC 识别的能力,以及 NIR-II 成像引导 CRC 切除的价值。
我们通过将抗 CEACAM5 纳米抗体(2D5)与近红外荧光染料 IRDye800CW 缀合,构建了探针 2D5-IRDye800CW。通过在小鼠血管和毛细血管模型中的成像实验,验证了 2D5-IRDye800CW 在 NIR-II 下的性能和优势。然后,构建了小鼠结直肠癌皮下肿瘤模型(n=15)、原位模型(n=15)和腹膜转移模型(n=10),以研究探针的体内分布和 NIR-I 与 NIR-II 之间的成像差异,并通过 NIR-II 荧光引导肿瘤切除。新鲜的人类结直肠癌标本与 2D5-IRDye800CW 孵育,以验证其特异性靶向能力。
2D5-IRDye800CW 具有延伸至 1600nm 的 NIR-II 荧光信号,与 CEACAM5 具有 2.29nM 的亲和力。在体内成像中,2D5-IRDye800CW 在 15 分钟内迅速在肿瘤中积累,并能特异性识别原位结直肠癌和腹膜转移。所有肿瘤均在 NIR-II 荧光引导下切除,甚至可以检测到小于 2mm 的肿瘤,NIR-II 的肿瘤与背景比(2.55±0.38,1.94±0.20)高于 NIR-I。2D5-IRDye800CW 可以精确识别 CEACAM5 阳性的人类结直肠癌组织。
2D5-IRDye800CW 结合 NIR-II 荧光具有转化潜力,可以帮助提高结直肠癌的 RO 手术水平。
本研究得到了北京市自然科学基金(JQ19027)、国家重点研发计划(2017YFA0205200)、国家自然科学基金(NSFC)(61971442、62027901、81930053、92059207、81227901、82102236)、北京市自然科学基金(L222054)、中国科学院青年创新促进会(JCTD-2021-08)、中国科学院战略性先导科技专项(XDA16021200)、珠海市高水平卫生人才团队项目(Zhuhai HLHPTP201703)、中央高校基本科研业务费(JKF-YG-22-B005)和首都临床特色应用研究(Z181100001718178)的支持。作者要感谢多模态生物医学成像实验平台、中国科学院自动化研究所提供的仪器和技术支持。